A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Trial Profile

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 12 Sep 2017 Interim results in patients with metastatic urothelial cancer (n=41), presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Interim results from patients with metastatic urothelial cancer (n=41) published in an Immunomedics Media Release
    • 16 Aug 2017 According to an Immunomedics media release, interim results from patients with metastatic urothelial cancer will be presented at the European Society for Medical Oncology 2017 Congress (ESMO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top